What's up pussy cat?

Teva announced that it would be slashing its dividend by 75% to $0.085 per quarter. As one of the top income stocks in the industry, this didn't sit well with investors.

Needless to say, Wall Street piled on the downgrades, money managers fled from the stock, and investors joined in the exodus.

 

Either your internet broke today, you live in TX of FL but clearly you're a troll but regardless might want to refresh your browser on the markets today. It's only the beginning; and if you knew anything about finances the "talk" of slashing "our" dividend has been rumored for a long time. Stock dropped because institutional brokerage firms followed one another to get out take profits and as seen today come back at a lower price to make more money.
Don't tell anyone but that's a principle economic 101 lesson for you..."buy low sell high". You're welcome now get back to selling your drug that kills people unlike ours.

 

True Dat !

 

Maybe "your" stock dropped because "Teva also has a weak drug pipeline that has been blitzed by repeated setbacks as its flagship MS therapy Copaxone is expected to lose ground to growing generic competition"
Econ 201: Cut your losses and sell Teva stock before it looses 50% of it's value in one month. Too late.

Your welcome now get back to selling YOUR inferior drug. Oh wait, your not successful at that any more.

 

I'm thinking you need to stop by English 101 because as confused as you sound "you're" and "your" are not to be used in the same manner. I'm sure at your Genentech meetings they barely tell you anything but do your homework before making a complete ignorant backwoods hillbilly statements that you are here

 

Always a strong response to be the grammar/typo cop. Great Job!

 

lame ass response from a lame ass, lazy Genentech rep....how odd. Andy or the record, I'm not trying to be the "grammar police" anymore than YOUR ignorant comments previously and pathetically posted attempt of labeling me as some irrelevant comment about the meds we sell which you call "inferior" however for some strange reason we remain #1. Suck that and take a puff puff before another patient of "YOURS" dies from your shitty& "inferior" meds. ( Drop)

 

Your maturity is profound. Furthermore (or as you might say "Andy or". Should you go back to English 101?) your slimy tactics not only provide evidence that your product is truly inferior but those tactics have demonstrated to others in the industry that you are what you are: Unethical, slimy, cheating, and an embarrassment to the industry. Good luck when this ship sinks.

 

After a tumultuous month that featured the announcement of thousands of layoffs and big slashing to Teva’s guidance and dividend, to investors...............are you gone sassy grammar cop?

 

I guess I must be missing something here? The grammar cop guy is attacking Genentech? What did I miss to draw the conclusion that it was somebody from Genentech posting? Sounds more like a Biogen Rep to me. I have found they are the ones that hate our success the most. I'm not even sure Genentech knows who we are, and most likely could care less about Copaxone. The Genentech Reps I have run into in the field seem pretty cool, and I know our guys that left here to go to Genentech are also pretty cool. I would suggest grammar cop manager launch at our true enemy, Biogen. They are the slime buckets that play dirty.

 

Huh? Are they still telling you guys Copaxone is Number 1 ? LMAO. You might want to look closely at those manipulated sales sheets, or slides they are showing you at the lameass meetings. IF Copaxone was still Number 1, the stock wouldn't be at $16 freaking dollars a share! LMAO. It really isn't rocket science, but the koolaid drinkers are now finding out that retirement plan based on Teva Stock just snuck up and bit you huh? $16 dollars a share???

 

Regardless of Cop 40 market share, the reps are what most would call "not good"

 

2 TN per most trrritories and usually that's 2 too many ... they're useless service reps not sales reps their sales force should be easily cut by 50% or more!

 

The reps are not even worth 16 dollars a share.

 

How are those Austedo prescriptions coming along?

 

Hell of a lot faster than that other shit indicated for TD that every doctor in America is laughing at including the ones that Neuropins are trying to pay off

 

I've heard different, unfortunately. Full transparency- the vast majority of the docs I've spoken with have indicated aust is another tool, which is good, but will likely be a secondary option for most patients - due to complex titration (so called "flexible dosing") regimen, dosing, no concomitant anticholinergic use in our study, fear of AEs and lesser efficacy than valb. Wish this wasn't the case!

 

Thanks for checking in Neurocrine rep. You obviously do not work here.

 

"Now Teva is facing a serious showdown for its franchise branded drug at a time it’s been hindered by price erosion in its own generic portfolio. The Israeli company has been forced to restructure this year, with a weak pipeline and a key clinical failure for its MS drug successor this year.

Teva’s shares $TEVA dropped 13% this morning."


I am holding out for $10 a share how about you? Although even that sounds risky!

 

Unbiased observations relaying 3rd party feedback from providers. If you have nothing better to do than make unfounded accusations, I suggest you consider spending that time engaging in more constructive interactions with your customers.... Aust has a place in the TD market, focus on that and educating your providers, rather than trolling comments on CF jumping to petty conclusions/accusations. If you can't accept honest feedback than I am inclined to question your ethical standards.